Durable remission with salvage second autotransplants in patients with multiple myeloma

Cancer

Volumn 118, Issue 14, 2012, Pages 3549-3555

  Shah, Nina ^a   Ahmed, Fraz ^a   Bashir, Qaiser ^a   Qureshi, Sofia ^a   Dinh, Yvonne ^a   Rondon, Gabriela ^a   Wen, Sijin ^a   Thall, Peter ^a   Khan, Hassan ^b   Giralt, Sergio ^c   Champlin, Richard ^a   Qazilbash, Muzaffar H ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

myeloma; salvage therapy; toxicity; transplantation

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GEMCITABINE; IMMUNOGLOBULIN G; LENALIDOMIDE; LEVOFLOXACIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; THIOTEPA; TOPOTECAN; VALACICLOVIR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BRADYCARDIA; CANCER REGRESSION; CHROMOSOME ABERRATION; CLINICAL ARTICLE; DEATH; DIARRHEA; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; HYPOTENSION; INFECTION; MAINTENANCE THERAPY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SALVAGE THERAPY; SUPRAVENTRICULAR TACHYCARDIA; UNITED STATES; WHOLE BODY RADIATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETREATMENT; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84863337258     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26662     Document Type: Article

References (36)

1. Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2006.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97. (Pubitemid 26240110)
3. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883. (Pubitemid 36532313)
4. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004; 104: 3052-3057. (Pubitemid 39507119)
5. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B,. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009; 101: 100-106.
6. Kyle RA, Rajkumar SV,. Multiple myeloma. Blood. 2008; 111: 2962-2972.
7. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B,. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995; 16: 7-11.
8. Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006; 106: 1084-1089.
9. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009; 43: 417-422.
10. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant. 1998; 21: 887-892. (Pubitemid 28200854)
11. Rosenbeck LL, Srivastava S, Kiel PJ,. Peripheral blood stem cell mobilization tactics. Ann Pharmacother. 2010; 44: 107-116.
12. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473. (Pubitemid 44264086)
13. Randles R, Wolfe D,. Introduction to the Theory of Nonparametric Statistics: New York, NY: John Wiley & Sons; 1979.
14. Fisher R,. On the interpretation of π2 from contingency tables, and the calculation of P. J R Stat Soc. 1922; 85: 87-94.
15. Kaplan E, Meier P,. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
16. Mantel N,. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
17. Schwarz G,. Estimating the dimension of a model. Ann Stat. 1978; 6: 461-464.
18. Venables WN, Ripley BD,. Modern Applied Statistics With S-PLUS. 3rd ed. New York, NY: Springer; 1999.
19. Munshi NC, Anderson KC, Bergsagel PL, et al. Guidelines for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117: 4696-4700.
20. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ,. The role of second autografts in the management of myeloma at first relapse. Haematologica. 2006; 91: 141-142. (Pubitemid 43235400)
21. Mikhael JR, Samiee S, Stewart K, et al. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: improved outcomes in patients with longer disease free interval after first ASCT [abstract]. Blood. 2007; 110. Abstract 946.
22. Simpson L, Verma R, Kumar S, Lacy M, et al. Outcome after second stem cell transplantation for relapsed multiple myeloma [abstract]. J Clin Oncol. 2007; 25. Abstract 8118.
23. Burzynski JA, Toro JJ, Patel RC, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma. 2009: 50: 1442-1447.
24. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008.
25. Shah N, Weber D, Alexanian R, et al. Survival disparities between African-American and Caucasian patients with multiple myeloma are blunted in the era of novel therapeutics and autologous stem cell transplantation. Paper presented at: American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, La.
26. Sirohi B, Powles R, Kulkarni S, et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001; 28: 29-37. (Pubitemid 32707614)
27. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357: 2133-2142. (Pubitemid 350146108)
28. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357: 2123-2132. (Pubitemid 350146107)
29. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498. (Pubitemid 41007864)
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617. (Pubitemid 36741588)
31. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of 2 doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004; 127: 165-172. (Pubitemid 39371809)
32. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25: 3892-3901. (Pubitemid 47477266)
33. Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol. 2008; 87: 623-631.
34. Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ,. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007; 92: 1149-1150. (Pubitemid 350144228)
35. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007; 138: 330-337. (Pubitemid 47035389)
36. Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008; 26: 4777-4783.